红龙根汤联合依达拉奉右莰醇对溶栓后脑梗死患者进展性脑梗死风险的影响  

Effect of Honglonggen Decoction Combined with Edaravoneand Dexborneol in Patients with Progressive Cerebral Infarction Risk After Thrombolysis

作　　者：雷萌 耿纪超 朱杰 孔静波 LEI Meng;GENG Jichao;ZHU Jie;KONG Jingbo(The Third People′s Hospital of Henan Province,Zhengzhou Henan China 450000)

机构地区：[1]河南省直第三人民医院,河南郑州450000

出　　处：《中医学报》2024年第12期2678-2684,共7页Acta Chinese Medicine

基　　金：2023年度河南省医学科技攻关计划联合共建项目(LHGJ20230672)。

摘　　要：目的:观察红龙根汤联合依达拉奉右莰醇对溶栓后脑梗死患者进展性脑梗死风险的影响。方法:81例脑梗死溶栓后患者采用动态随机化法分为对照组40例和观察组41例。对照组溶栓后给予依达拉奉右莰醇注射液,观察组在对照组治疗基础上给予红龙根汤。比较两组患者美国国立卫生研究院卒中量表(National Institutes of Health Stroke Scale,NIHSS)评分、日常生活活动能力(activities of daily living,ADL)评分、临床疗效、不良反应及神经生长因子(nerve growth factor,NGF)、高敏-C反应蛋白(high sensitive C-reactive protein,hs-CRP)、衰老关键蛋白抗原-5(Fibulin-5)、基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)、1,25-二羟维生素D3[1,25-dihydroxyvitamin D3,1,25-(OH)2-VitD3]、脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2,Lp-PLA2)、胶质纤维酸性蛋白(glial fibrillary acidic protein,GFAP)。结果:治疗后,两组患者NIHSS评分显著降低,ADL评分显著升高(P<0.05);观察组NIHSS评分低于同期对照组,ADL评分高于同期对照组(P<0.05)。治疗后,两组患者hs-CRP、MMP-9、Lp-PLA2、GFAP显著降低(P<0.05),NGF、Fibulin-5显著升高(P<0.05);观察组hs-CRP、MMP-9、Lp-PLA2、GFAP低于同期对照组(P<0.05),NGF、Fibulin-5高于同期对照组(P<0.05)。观察组进展性脑梗死发生率低于同期对照组(P<0.05),梗死症状明显改善率高于同期对照组(P<0.05)。两组患者累计不良反应发生率比较,差异无统计学意义(P>0.05)。结论:红龙根汤联合依达拉奉右莰醇治疗溶栓后脑梗死患者有神经保护作用,可改善患者神经功能,降低进展性脑梗死风险。Objective:To observe the effect of Honglonggen Decoction combined with EdaravoneandDexborneol on risk of progressive cerebral infarction in patients with cerebral infarction after thrombolysis.Methods:81 patients with cerebral infarction after thrombolysis were divided into 40 cases in the control group and 41 cases in the observation group by dynamic randomization method.The control group was given Edaravone/(+)-2-Decanol injection after thrombolysis,and the observation group was given Honglonggen Decoction based on the treatment of the control group.The National Institutes of Health Stroke Scale(NIHSS)scores were compared between the two groups.The two groups were compared in terms of National Institutes of Health Stroke Scale(NIHSS)scores,activities of daily living(ADL)scores,clinical efficacy,adverse effects,and nerve growth factor(NGF),highly sensitive C-reactive protein(HSCRP),and nerve growth factor(NGF),and highly sensitive C-reactive protein(HSCRP).The highly sensitive C-reactive protein(hs-CRP),Fibulin-5,matrix metalloproteinase-9(MMP-9),1,25-dihydroxyvitamin D3(1,25-dihydroxyvitamin D3),and other factors that are important for the development of ADLs,clinical efficacy,adverse effects,and nerve growth factor(NGF),high sensitive C-reactive protein(hs-CRP),and the development of a new neurotransmitter dihydroxyvitamin D3,[1,25-(OH)2-VitD3],lipoprotein-associated phospholipase A2(Lp-PLA2),glial fibrillary acidic protein(GFAP),and GFAP.protein(GFAP).Results:After treatment,the NIHSS scores of the two groups of patients were significantly reduced and the ADL scores were significantly increased(P<0.05);the NIHSS scores of the observation group were lower than those of the control group in the same period,and the ADL scores were higher than those of the control group in the same period(P<0.05).After treatment,hs-CRP,MMP-9,Lp-PLA2,and GFAP were significantly lower(P<0.05),and NGF and Fibulin-5 were significantly higher(P<0.05)in both groups;hs-CRP,MMP-9,Lp-PLA2,and GFAP were lower than those in the same period

关 键 词：脑梗死 红龙根汤 依达拉奉右莰醇 进展性脑梗死 静脉溶栓 

分 类 号：R277.743.3[医药卫生—中医学]